Endymed Ltd (TASE: ENDY), currently traded on the Tel Aviv Stock Exchange, is proud to announce that it has been granted FDA approval for the marketing and sales of Pure Laser, a new hair removal device in the United States.
The Pure Laser was developed in the Company’s labs by its subsidiary Endymed Medical Ltd. and is based on laser technology, designed to treat hair removal on all skin types. To obtain the approval, the Company conducted numerous clinical tests to evaluate the device’s safety and efficacy. The clinical tests were carried out in the Company’s R&D center and the outcomes were positive.
The Company intends to commence marketing in the US through its subsidiary, Endymed Medical Inc. and its marketing and sales team. Furthermore, the Company is working on registration and marketing of the device in other strategic countries, as well as establishing distribution agreements.
Pure Laser is the Company’s first laser-based device to receive FDA approval for marketing and sales within the US. It is a great addition to the Company’s Professional portfolio enhancing the variety of its aesthetic offering to both the Company’s partners and clients.
